ClinicalTrials.gg
Not yet recruitingNCT06166797Updated Dec 12, 2023

Elucidating Growth Hormone Dynamics at Stages of Progressive Nonalcoholic Fatty Liver Disease

An observational study in Nonalcoholic Fatty Liver Disease, sponsored by Massachusetts General Hospital. Not yet recruiting. Open to male participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-12.

Sponsored by Massachusetts General Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
60
Ages
18 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital — 2 open to participants now, 3 under way, 1 of them phase 3. Non-alcoholic Fatty Liver Disease · Massachusetts General Hospital.

Started
2023
with 1 other
Observational
Only one
of the 16
Registered
16th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital, this one is one of 2 that started in 2023, is the only observational one, and was the 16th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

2 of the 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 70 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to investigate relationships between the body's growth hormone "axis" and nonalcoholic fatty liver disease. The growth hormone "axis" includes the hormones growth hormone and insulin-like growth factor 1, and associated proteins. We hypothesize that there will be a relationship such that people with more advanced nonalcoholic fatty liver disease will have greater impairments in the growth hormone axis. There are no treatments associated with this research study.

Read the detailed description

Several lines of existing research implicate activity of the GH/IGF-1 axis in the development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in humans. Careful phenotyping of GH dynamics in individuals with NAFLD and NASH is required for comprehensive understanding of the degree to which perturbations in the GH axis contribute to the pathogenesis of NAFLD/NASH. The purpose of this research is to comprehensively assess GH dynamics in individuals across the spectrum of NAFLD to determine associations between the GH/IGF-1 axis and stages of disease progression in NAFLD.

03

Conditions studied

  • Nonalcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Men 18-70yo with or without nonalcoholic fatty liver disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Men 18-70yo

  • between 25kg/m2 - 40kg/m2.
  • antibody and surface antigen negative.
  • Meet inclusion criteria for one of Groups 1-3 based on medical history, laboratory criteria, and hepatic fat fraction (1H-MRS) and/or liver

    • Group 1: No NAFLD: no history of NAFLD/NASH, hepatic fat fraction \<5% on 1H-MRS, \< 30 U/L.
    • Group 2: Simple Steatosis: no history of NASH, hepatic fat fraction ≥10% on 1H-MRS, ALT \< 30 U/L.
    • Group 3: Nonalcoholic Steatohepatitis: Biopsy confirmed NASH within the year prior to study participation, with liver fibrosis stage 2 or 3 on biopsy.

Exclusion criteria

Exclusion criteria:

  • Heavy alcohol use defined as consumption of > 30mg daily for at least 3 consecutive months over the past 5 years
  • Type 1 diabetes, any use of insulin, or any use of other anti-diabetes medication except metformin or sulfonylurea. Individuals with Type 2 diabetes that is controlled by diet or by metformin and/or sulfonylurea will be eligible.
  • Use of any specific pharmacological treatments for NAFLD/NASH except vitamin E within the 3 months before screening visit.
  • Chronic systemic use in the ≤6 months prior to the baseline visit.
  • Chronic use of Actigall, methotrexate, amiodarone, or tamoxifen
  • Known diagnosis of alpha-1 antitrypsin deficiency, Wilson's disease, hemochromatosis, or hepatitis
  • Use of GH or GHRH within the past 6 months
  • Change in lipid lowering or anti-hypertensive regimen within 2 months of screening
  • \< 12.5 g/dL
  • Severe chronic illness judged by the investigator to present a to participation
  • History of hypopituitarism, head irradiation or any other condition known to affect the GH axis.
  • Use of testosterone or estrogen or progesterone unless physiologic stable testosterone use for at least 1 year prior to study entry
  • Routine MRI exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clip
  • Weight loss surgery within 1 year before baseline. Weight loss surgery more than 1 year prior to baseline visit is permissible if no active weight loss (\<10% decrease in weight over past 6 months)
  • Lack of fluency in English and/or inability to complete the consent process in English.
  • Judge by the investigator to be inappropriate for the study for other reasons not detailed above.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • No NAFLD

    individuals with \<5 percent hepatic fat fraction on magnetic resonance spectroscopy

  • Simple Steatosis

    individuals with at least 10% fat fraction on magnetic resonance spectroscopy without any history of nonalcoholic steatohepatitis or evidence of fibrosis

  • Nonalcoholic Steatohepatitis

    individuals with biopsy confirmed nonalcoholic steatohepatitis and stage 2 or 3 fibrosis

06

What researchers measure

Primary outcomes

  1. peak growth hormone

    peak growth hormone level during standard 3-hour glucagon stimulation test

    Time frame: at baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2023; primary completion for Jul 2024, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Dec 12, 2023
StartEst.
Dec 1, 2023
Primary completionEst.
Jul 31, 2024
CompletionEst.
Jul 31, 2024
Last update
Dec 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06166797
Responsible party
Takara Stanley (Associate Professor of Pediatrics, Massachusetts General Hospital) — Principal investigator
First posted
Dec 12, 2023
Start date
Dec 1, 2023 (estimated)
Primary completion
Jul 31, 2024 (estimated)
Completion
Jul 31, 2024 (estimated)
Last update
Dec 12, 2023

Study contacts

Takara L Stanley, MD
Contact
tstanley@mgh.harvard.edu
617-724-9109
Allison Arpante, NP
Contact
Steven Grinspoon, MD
principal investigator · Massachusetts General Hospital
Takara Stanley, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion